Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 08:00PM GMT
Release Date Price: $46.66 (+2.93%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good afternoon. My name is Gena Wang. I'm biotech analyst at Barclays. Welcome to our second Virtual Global Healthcare Conference. First, I wish everyone stay healthy, and I would like to thank all the participants, investors, companies and especially our event team and a corporate access team who made this virtual health care conference possible.

With that, I would like to introduce our next presenting company is Editas. With us today, we have Jim Mullen, Chief Executive Officer; Lisa Michaels, Chief Medical Officer; Michelle Robertson, Chief Financial Officer.

With that, I hand over to you, Jim, for a brief overview of the company.

James C. Mullen
Editas Medicine, Inc. - Chairman, President & CEO

Thank you very much, Gena. We're very happy to be here today. Thanks for hosting us. So let me give just a high-level overview, and then we'll go right to the questions and answers.

I think as most people know that are on this, Editas Medicine is really based on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot